FDA's ad­comm votes unan­i­mous­ly in fa­vor of Mod­er­na and Pfiz­er's Covid-19 vac­cines for the youngest chil­dren

The FDA’s VRB­PAC met Wednes­day in a tense meet­ing to de­cide the fate of both Pfiz­er/BioN­Tech and Mod­er­na’s Covid-19 vac­cines for the youngest groups of chil­dren, from ages 6 months to 6 years. Ul­ti­mate­ly, the com­mit­tee of 21 out­side ex­perts vot­ed unan­i­mous­ly in fa­vor of Mod­er­na’s two-shot vac­cine, and Pfiz­er’s three-shot vac­cine (both 21-0).

The ex­perts all ex­pressed sup­port for vac­ci­nat­ing chil­dren in this youngest pop­u­la­tion to bet­ter pre­vent against Covid-re­lat­ed hos­pi­tal­iza­tions and deaths that have risen in this group dur­ing the lat­est wave of the Omi­cron vari­ant.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.